Morbidity and Mortality after Induction Chemotherapy Followed by Surgery in IIIa-N2 non Small Cell Lung Cancer

被引:1
|
作者
Borreman, Ph. [1 ]
De Leyn, P. [1 ]
Decaluwe, H. [1 ]
Moons, J. [1 ]
Van Raemdonck, D. [1 ]
Nafteux, Ph. [1 ]
Coosemans, W. [1 ]
Lerut, T. [1 ]
机构
[1] Katholieke Univ Leuven Hosp, Dept Thorac Surg, Louvain, Belgium
关键词
Lung cancer; non-small-cell carcinoma; chemotherapy; adjuvant; pneumonectomy; PROLONGED AIR LEAK; PREOPERATIVE CHEMOTHERAPY; PULMONARY LOBECTOMY; COMORBIDITY SCORE; RESECTION; COMPLICATIONS; SYSTEM; PREDICTORS; THERAPY; POSSUM;
D O I
暂无
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective : To evaluate the frequency and risk of postoperative complications and mortality in patients with IIIa-N2 non small cell lung cancer after induction chemotherapy and surgery. Methods : In a surgical database records from ninety two patients, operated between January 1, 2000 and December 3 1, 2006 were reviewed. Univariate analysis was used to identify predictors of postoperative complications and in-hospital mortality. Results : All cases were histologically confirmed stage IIIa-N2. All patients received preoperative platinum based chemotherapy without radiotherapy. Pneumonectomy was performed in 20 cases (23.5%), from which 9 right sided. (Bi)lobectomy was performed in 53 cases (62.4%) and sleeve lobectomy in I I cases (17.2%). One wedge resection was performed (1.2%). In 7 cases (7.6%) only an exploration was done. Complications developed in 35 patients (38%). Major complications in 15 patients (16%). No bronchopleural fistulae were observed. Analysis identified increased age and high physiological and operative severity score for the enumeration of mortality and morbidity (POSSUM) as a risk factor to develop complications, and a high simplified comorbidity score as a risk factor to develop a major complication. Higher age, Charlson comorbidity index, simplified comorbidity score and POSSUM were a risk factor for developing pneumonia. Conclusion : Although surgery after induction therapy for IIIa-N2 NSCLC can be done with a morbidity and mortality comparable to surgery alone, it remains a high risk operation. It should therefore be performed in a center with experience. Bronchial stump protection should be used whenever there is an increased risk for developing a bronchopleural fistula. In deciding whether to do surgery or radiotherapy one should keep in mind the feasibility of performing a complete resection together with a preoperative assessment to predict complications and mortality. For the preoperative assessment several scoring systems can be used from which we find the simplified comorbidity score most useful.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [41] A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209)
    Nagai, K
    Tsuchiya, R
    Mori, T
    Tada, H
    Ichinose, Y
    Koike, T
    Kato, H
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 125 (02): : 254 - 260
  • [42] Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer:: A prospective pilot study
    Vansteenkiste, JF
    Stroobants, SG
    De Leyn, PR
    Dupont, PJ
    Verbeken, EK
    ANNALS OF ONCOLOGY, 1998, 9 (11) : 1193 - 1198
  • [43] RISK OF BILOBECTOMY AFTER NEOADJUVANT CONCURRENT CHEMORADIOTHERAPY FOR STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER
    Cho, Jong Ho
    Kim, Hong Kwan
    Kim, Jhingook
    Choi, Yong Soo
    Kim, Kwhanmien
    Shim, Young Mog
    Park, Keunchil
    Ahn, Yong Chan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S878 - S878
  • [44] Neoadjuvant Treatment Followed by Surgery Versus Chemoradiation in Stage IIIA-N2 Non-small Cell Lung Cancer on Behalf of GOECP/SEOR-GICOR
    Counago, F.
    Muniz, S. Montemuino
    Jove-Teixido, J.
    Taboada, B.
    Calvo-Crespo, P.
    Martin, M.
    Lopez, M.
    Ots, P. M. Samper
    Del Cerro, E.
    Lopez, J.
    CaNivano, T. GarcIa
    Diaz, V.
    Baron, L. De Ingunza
    Murcia, M.
    Alcantara, M.
    Corona, J.
    Puertas, M. M.
    Chust, M.
    Couselo, M. L.
    De Dios, N. Rodriguez
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E482 - E483
  • [45] A prospective phase II study of induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer
    Zhong, Wenzhao
    Yang, Xuening
    Liao, Riqiang
    Nie, Qiang
    Su, Jian
    Chen, Zhihong
    Zhang, Xuchao
    An, Shejuan
    Zhou, Qing
    Yang, Jinji
    Wu, Yi Long
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Induction erlotinib or gemcitabine/carboplatin factorial assignment therapy in stage IIIA-N2 non-small cell lung cancer
    Zhong, W.
    Yang, X.
    Liao, R.
    Nie, Q.
    Dong, S.
    Su, J.
    Zhang, X.
    Zhou, Q.
    Yang, J.
    Wu, Y. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] A PROSPECTIVE PHASE II STUDY OF INDUCTION ERLOTINIB THERAPY IN STAGE IIIA-N2 NON-SMALL-CELL LUNG CANCER
    Zhong, W. -Z.
    Yang, X. -N.
    Liao, R. -Q.
    Nie, Q.
    Su, J.
    Zhang, X. -C.
    An, S. -J.
    Zhou, Q.
    Yang, J. -J.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2012, 23 : 43 - 43
  • [48] What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?
    Van Meerbeeck, Jan P.
    De Pauw, Rebecca
    Tournoy, Kurt
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (02) : 199 - 206
  • [49] Risk Factors of Brain Metastases in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection
    Sun, S.
    Men, Y.
    Yang, X.
    Sun, X.
    Zhao, M.
    Yuan, M.
    Bao, Y.
    Ma, Z.
    Liu, Y.
    Hui, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E452 - E453
  • [50] Survival of Patients with Persistent N1 or N2 Disease After Induction Therapy for Stage IIIA-N2 Non-Small-Cell Lung Cancer
    Beqari, J.
    Potter, A.
    Pan, M.
    Copeland, J.
    Lanuti, M.
    Yang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S884 - S884